Wegovy 0.25mg: What Does the Starting Dose Actually Do?

Why does Wegovy begin at 0.25mg rather than a higher dose?

It is a common assumption that the first pen you receive is where treatment begins in any meaningful sense. In reality, the 0.25mg dose sits at the very beginning of the titration ladder purely to reduce the likelihood of side effects early on. Semaglutide slows the rate at which your stomach empties, which is part of how it reduces appetite, but that same mechanism can cause nausea, vomiting or digestive discomfort if the body encounters it too quickly at a higher concentration.

Starting at 0.25mg gives your system four weeks to adapt before the prescriber moves you upward. The full Wegovy dose schedule progresses through 0.5mg, 1mg, a step that many patients find is where appetite suppression becomes more noticeable, 1.7mg and 2.4mg, with each increase separated by roughly a month. The 7.2mg single-dose pen, approved by the MHRA in April 2026, sits above that for eligible adults whose prescriber determines they need it. At 0.25mg, you are not yet at a dose the clinical trials identified as therapeutically significant for weight reduction, and that is intentional design, not a limitation of your particular prescription.

A question our prescribers hear regularly is whether patients can begin at a higher dose to get results sooner. The answer is no: the schedule is clinically determined, and moving faster increases the risk of gastrointestinal side effects severe enough to interrupt treatment entirely. The slower path is the faster one in practice.

What side effects are most likely during the 0.25mg phase?

The side-effect profile of semaglutide is dominated by gastrointestinal effects, nausea, loose stools, constipation, indigestion and burping are the most frequently reported. During the 0.25mg phase these are generally milder than at higher doses, because the concentration is lower, but they can still appear in the first days after each weekly injection.

For most people, symptoms are most noticeable in the first week or so after starting and ease as the body adapts. Eating smaller meals, avoiding high-fat foods, and staying well hydrated all help. The nume FAQs page covers practical tips that prescribers share with patients during aftercare. If symptoms are severe or persistent (particularly severe stomach pain that spreads to the back) you should seek medical attention promptly. The MHRA highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines in a Drug Safety Update issued in January 2026; it remains something to know about rather than something to expect.

Injection-site reactions (redness, mild swelling at the site) are also possible. Rotate between the abdomen, thigh and upper arm to reduce this. The NHS semaglutide patient page lists side effects clearly and is worth reading before your first injection.

Can you stay on 0.25mg for longer than four weeks if it's working?

This is precisely where the misconception worth setting straight arises. Some people feel well at 0.25mg (little nausea, no disruption) and wonder whether staying put is sensible. The 0.25mg dose is not a therapeutic maintenance dose under the licensed schedule; if you want to understand how the different Wegovy mg options compare across the titration pathway, that context helps explain why the clinical evidence for weight management was built at 2.4mg (and above). Staying indefinitely at 0.25mg because it feels comfortable is unlikely to produce the outcomes the treatment is designed for.

That said, if your prescriber judges that a slower titration is clinically appropriate for you (perhaps because side effects have been difficult at a previous step) the pace can be adjusted. That is a clinical conversation, not a decision to make alone. The question of staying on the same Wegovy dose is covered in more detail for anyone weighing that up.

On the other hand, if you are tolerating 0.25mg with no issues at all after your four weeks, that is a good sign, it suggests the next step upward is likely to be manageable too. Your prescriber reviews your progress before every dose change, including at num.

How does eligibility for Wegovy at any dose work in the UK?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The 0.25mg starting dose is part of the same licensed pathway regardless of which maintenance dose the prescriber eventually targets, and people often ask about 2 mg Wegovy specifically, as it is the penultimate step before the full maintenance dose.

NICE recommends semaglutide (TA875) within specialist weight management services on the NHS, with a two-year maximum duration; waiting lists are long in most areas. Private treatment through a regulated pharmacy offers an alternative for people who do not meet the current NHS criteria or prefer not to wait. If you are considering the weight-loss treatments available through a private consultation, eligibility is assessed by a GPhC-registered prescriber before anything is prescribed, not by a form or an algorithm. The NICE appraisal of semaglutide (TA875) sets out the NHS recommendation in full.

For a broader look at the cost of Wegovy in a private setting, the weight-loss overview explains what is typically included in a private prescription price. Check your eligibility through a free consultation if you want a clinical view on whether this treatment is right for you.